TWiV 1156: Clinical update with Dr. Daniel Griffin
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In his weekly clinical update, Dr. Griffin updates us about polio SIA campaign in Gaza, the durability of protection following administration of GSK's recombinant antigen RSV vaccine, mpox in an Ugandan jail, the Marburg virus outbreak in Rwanda, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, immunogenicity, reactogenicity and safety of different COVID-19 vaccine platforms, disease severity in those not previously vaccinated with those vaccinated but not infected, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, if COVID-19 doubles the risk for heart attacks, stroke and death and if COVID-19 affects the regions of the brainstem.
Subscribe (free): Apple Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Polio: second round of vaccination in Gaza (Reuters)
- Season 3 for GSK RSV vaccine protection (CIDRAP)
- Positive data for Arexvy, the respiratory syncytial virus vaccine (GSK)
- Mpox convicted felon: in Ugandan prison (Reuters)
- How to stop Marburg virus (Rwanda Biomedical Centre)
- Marburg virus fact sheet (Rwanda Biomedical Centre)
- CDC summary of the "Rwanda Marburg Situation" (CDC)
- 700 doses of a Marburg vaccine from the Sabin Vaccine Institute to Rwanda (CIDRAP)
- USAID mobilizes Marburg outbreak response in Rwanda (United States Agency International Development)
- COVID-19 deaths (CDC)
- COVID-19 national and regional trends (CDC)
- Waste water scan for 11 pathogens (WastewaterSCan)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- PICOBOO: immunogenicity, reactogenicity and safety of different COVID-19 vaccine (Journal of Infection)
- COVID-19 in previously unvaccinated compared with previously uninfected vaccinated (JID)
- New preventive COVID-19 agent (ISDA)
- IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- COVID Data tracker (CDC
- Differences in COVID-19 outpatient antiviral treatment (MMWR)
- Drug interaction checker (University of Liverpool)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- COVID-19 is a coronary artery disease with genetic interaction with ABO blood type (AHAIASA Journals)
- COVID-19 doubles risk of heart attack, stroke and death (EurekaAlert!)
- QTL mapping at 7T in COVID-19: brainstem and outcomes (Brain)
- Letters read on TWiV 1156
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]